LENZ Therapeutics (LENZ) Free Cash Flow (2020 - 2026)
LENZ Therapeutics (LENZ) reported Free Cash Flow of -$33.6 million for Q1 2026, down 107.93% year-over-year from $423.5 million in Q1 2025, and down 1.62% quarter-over-quarter from -$33.1 million in Q4 2025.
LENZ Therapeutics (LENZ) Free Cash Flow (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has 7 years of Free Cash Flow data on file, last reported at -$33.6 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$33.6 million, down 107.93% year-over-year; the trailing twelve-month figure through Mar 2026 was -$87.4 million (down 68.75% YoY), and the FY2025 annual result was -$70.0 million, down 17.46% from the prior year.
- Free Cash Flow slipped to -$33.6 million in Q1 2026 per LENZ's latest filing, from -$33.1 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$9.0 million in Q3 2025 and troughed at -$33.6 million in Q1 2026.
- A 5-year average of -$18.7 million and a median of -$16.2 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow soared 55.89% in 2024, then plunged 257.48% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$23.4 million in 2022, then increased by 10.58% to -$21.0 million in 2023, then soared by 55.89% to -$9.2 million in 2024, then sank by 257.48% to -$33.1 million in 2025, then slipped by 1.62% to -$33.6 million in 2026.
- Business Quant data shows LENZ's Free Cash Flow at -$33.6 million in Q1 2026, -$33.1 million in Q4 2025, and -$9.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | LENZ Therapeutics | 192.19 Mn | 192.19 Mn | 825,000.00 | -33.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.60 Mn |
| Mar 31, 2026 | -33.60 Mn |
| Dec 31, 2025 | -33.06 Mn |
| Dec 31, 2025 | -33.06 Mn |
| Sep 30, 2025 | -9.03 Mn |
| Sep 30, 2025 | -9.03 Mn |
| Jun 30, 2025 | -11.75 Mn |
| Jun 30, 2025 | -11.75 Mn |
| Mar 31, 2025 | -16.16 Mn |
| Mar 31, 2025 | -16.16 Mn |
| Dec 31, 2024 | -9.25 Mn |
| Dec 31, 2024 | -9.25 Mn |
| Sep 30, 2024 | -10.48 Mn |
| Sep 30, 2024 | -10.48 Mn |
| Jun 30, 2024 | -15.93 Mn |
| Jun 30, 2024 | -15.93 Mn |
| Mar 31, 2024 | -23.94 Mn |
| Mar 31, 2024 | -23.94 Mn |
| Dec 31, 2023 | -20.97 Mn |
| Dec 31, 2023 | -20.97 Mn |